Catalogo dei prodotti della ricerca

FILETTI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.390
EU - Europa 699
AS - Asia 207
AF - Africa 23
SA - Sud America 13
OC - Oceania 2
Totale 2.334
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.376
IT - Italia 316
SE - Svezia 181
IN - India 98
SG - Singapore 59
BG - Bulgaria 39
DE - Germania 37
FI - Finlandia 35
CN - Cina 23
TG - Togo 18
RO - Romania 15
CA - Canada 12
GB - Regno Unito 12
UA - Ucraina 12
AR - Argentina 11
ES - Italia 11
BE - Belgio 8
HK - Hong Kong 8
FR - Francia 6
JP - Giappone 6
IR - Iran 5
NL - Olanda 5
TR - Turchia 5
DK - Danimarca 4
IE - Irlanda 4
RU - Federazione Russa 4
CH - Svizzera 3
PL - Polonia 3
AU - Australia 2
EG - Egitto 2
MX - Messico 2
ZA - Sudafrica 2
AM - Armenia 1
AT - Austria 1
AZ - Azerbaigian 1
BR - Brasile 1
CL - Cile 1
GR - Grecia 1
IL - Israele 1
NG - Nigeria 1
NO - Norvegia 1
RS - Serbia 1
Totale 2.334
Salva come PNG Salva come JPEG
Città #
Fairfield 244
Chandler 119
Ashburn 107
Rome 88
Seattle 77
Houston 71
Woodbridge 71
Cambridge 68
Wilmington 64
Princeton 53
San Paolo di Civitate 42
New York 40
Sofia 39
Ann Arbor 34
Helsinki 34
Lawrence 33
Boston 28
Milan 26
San Diego 26
Millbury 22
Lomé 18
Dearborn 16
Andover 14
Singapore 13
Bremen 11
Federal 11
Beijing 10
Toronto 10
Boardman 8
Brussels 8
Norwalk 8
Rizziconi 8
Fremont 7
Madrid 7
Turin 7
Des Moines 6
Hong Kong 6
London 6
Morlupo 6
Padova 6
Bühl 5
Grafing 5
Istanbul 5
Plano 5
Pune 5
Barcelona 4
Bloomfield Hills 4
Dublin 4
Mantova 4
Washington 4
Bari 3
Catania 3
Leawood 3
Los Angeles 3
Marino 3
Naples 3
Phoenix 3
Ponte San Pietro 3
Redwood City 3
Sacramento 3
Syracuse 3
Trumbull 3
Bern 2
Bra 2
Breda 2
Castelraimondo 2
Central 2
Durham 2
Hyderabad 2
Imola 2
Kalāheo 2
Kashan 2
Kilburn 2
Laurel 2
Lublin 2
Lucera 2
Mexico City 2
Muizenberg 2
New Delhi 2
Niigata 2
Nærum 2
Olinda 2
Ortona 2
Paliano 2
Parma 2
Raleigh 2
Rieti 2
Takamatsu 2
Thiene 2
White Plains 2
Angoulême 1
Arezzo 1
Arnsberg 1
Arzano 1
Augusta 1
Baku 1
Basel 1
Beauharnois 1
Berlin 1
Biella 1
Totale 1.619
Salva come PNG Salva come JPEG
Nome #
A simplified genomic profiling approach predicts outcome in metastatic colorectal cancer 138
Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinoma 86
Correction to. Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinoma 86
Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition 78
Predictive biomarkers for checkpoint inhibitor-based immunotherapy: The Galectin-3 signature in NSCLCs 76
Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma 76
Unexpected serious aplastic anemia from PD-1 inhibitors. beyond what we know 69
Impact of tumor site on the prognosis of small bowel adenocarcinoma 68
Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study 67
CT based radiomic approach on first line pembrolizumab in lung cancer 66
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 65
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 59
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification 57
null 54
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden 54
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 54
New driver alterations in non-small cell lung cancer. A narrative review 52
Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression ≥ 50% and their relationship with clinical outcomes 52
null 50
High prevalence and early occurrence of skeletal complications in EGFR mutated NSCLC patients with bone metastases 50
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes 46
Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives 45
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%. A multicenter study with external validation 44
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors. the multicenter FAMI-L1 study 44
Prophylactic use of antiemetics for prevention of opioid-induced nausea and vomiting. a survey about Italian physicians’ practice 43
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors. A multicentre analysis of immune-related adverse events 42
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 41
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 41
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: a case-control matched analysis from a large multicenter study 41
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: the multicenter retrospective CLARITY study 40
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 40
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 39
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors. Prospective analysis from a multicentre observational trial by FICOG 36
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study 36
Statins and immunotherapy. Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC 34
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 33
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients. a multicenter study of clinicians’ attitudes 31
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer 30
Breast cancer drug approvals issued by EMA: a review of clinical trials 30
Resolution of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) during Nivolumab therapy for non-small cell lung cancer. a case report 28
Comprehensive genomic profiling in large cell neuroendocrine lung cancer: the times they are a-changin' 27
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care. a national survey 26
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 25
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer 24
TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER IMMUNOCHEMOTHERAPY AND IBRUTINIB. 24
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 24
Health as a human right, the right to life and the freedom to choose 23
CDKN2A/B gene loss and MDM2 alteration as a potential molecular signature for hyperprogressive disease in advanced NSCLC: A next-generation-sequencing approach 21
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario 20
DNA damage response and repair (DDR) gene mutations as an alternative mechanism to generate high TMB in never smoker NSCLC patients 19
The use of fentanyl in pain management in head and neck cancer patients. a narrative review 19
null 17
EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO) 13
10P Family history of cancer correlates with improved outcome from immunotherapy in NSCLC independent of somatic DNA damage response gene status 13
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors among Patients Aged 80 Years or Older with Cancer: A Multicenter International Cohort Study 13
966P Diabetes therapy burden as proxy of impairment of immune checkpoint inhibitors efficacy 12
133P ARID1A-mutated cancers: New prospectives for treatment of a subgroup of gynecological cancer 12
Efficacy and safety of Antiemetic Regimens for Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Network Meta-Analysis 12
Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years 12
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature 11
[Medical cannabis. Facilitate the proposal and sustainability for the training of healthcare personnel and the conduct of clinical trials in the cancer population.] 11
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 11
Molecular Profile and Matched Targeted Therapy for Advanced Breast Cancer Patients 10
Clinical and psychometric validation of the BreSAS questionnaire module for symptom assessment among breast cancer survivors 10
null 10
null 10
ACCESS TO EARLY PHASE CLINICAL TRIALS AT THE TIME OF THE COVID-19 PANDEMIC: AN ITALIAN SURVEY 9
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy 9
Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study 9
Palliative sedation and time to death in home palliative care: retrospective analysis 8
1576P Efficacy of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A network meta-analysis 8
Pandemic phase-adjusted analysis of COVID-19 outcomes reveals reduced intrinsic vulnerability and substantial vaccine protection from severe acute respiratory syndrome Coronavirus 2 in patients with breast cancer 7
Patients' Satisfaction with Breakthrough Cancer Pain Therapy. A Secondary Analysis of IOPS-MS Study 6
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 5
Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings 5
Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile 5
La medicina di precisione come opera d’arte collettiva 4
New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis 3
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 2
Totale 2.630
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.557
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.557
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201941 0 0 0 0 0 0 0 0 0 0 22 19
2019/2020301 14 10 8 11 31 38 42 32 37 44 14 20
2020/2021428 8 17 4 4 11 11 35 81 34 33 58 132
2021/2022641 18 8 29 26 65 35 32 42 57 37 198 94
2022/2023716 125 149 57 57 66 67 11 94 47 6 23 14
2023/2024460 23 48 15 61 56 102 34 63 3 52 3 0
Totale 2.630